Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Livalo AG Skips NHI Price Listing Again, Sandoz Won’t Comment on Diovan AG
August 27, 2013
- Astellas Launches Tacrolimus Extended-Release Capsules Astagraf XL in US
August 27, 2013
- LEO Pharma Files NDA for Psoriasis Drug, Paving Way for Full Foray into Japan Market
August 27, 2013
- Announcement: Oncology Japan 2013 to Be Held on November 5, 6
August 27, 2013
- Affinity Gel Market to Triple in 2017: Fuji Chimera Research Institute
August 26, 2013
- Somatropin BS SC Injection Approved for Full Range of Indications with Additional Indications: Sandoz
August 26, 2013
- Plavix, Diovan Rank 1st, 3rd in Japan Ethical Drugs Sales in April-June: IMS Japan
August 26, 2013
- Eisai Files Petition with US Court to Nudge DEA over Stalled Scheduling of Fycompa
August 23, 2013
- OrphanPacific to Launch Normosang, Second Ultra Orphan Drug, on Aug. 23
August 22, 2013
- Patent Cliff Hits Major Global Drug Makers, Weak Yen Weighs on Japan Sales
August 22, 2013
- Ajinomoto Obtains Approval for CCB Atelec Tab. 20
August 22, 2013
- Kowa Receives Approval for Livalo OD Tablets 4 mg in Japan
August 22, 2013
- G-CSF Biosimilars Now on the Market; a Three-way Battle Begins
August 21, 2013
- Biosimilars to a Number of Major Drugs Including Remicade and Avastin Now in Development or in Preparation for Development
August 21, 2013
- Increasing Awareness of Biosimilars to Establish Them as a New Category; Companies Forming Alliances to Build Development and Marketing System
August 21, 2013
- Zeria Obtains Exclusive Rights in Japan for Iron Deficiency Treatment Ferinject from Vifor Pharma of Switzerland
August 21, 2013
- ASKA to Roll Out Generics of Takeda Product for 1st Time
August 20, 2013
- M3 to Team Up with Yahoo Japan on Healthcare Advertising Business
August 20, 2013
- Diovan Generics Developed as AGs, “No Comment” on December Listing: Sandoz
August 20, 2013
- BMKK, AZ Join the Fray in the Domestic Diabetes Market; Will Build Their Foundation on Byetta, Bydureon
August 20, 2013
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…